European regulators conclude tirzepatide causes dysesthesia and delayed gastric emptying

European Union regulators have concluded that tirzepatide — the active ingredient in Mounjaro and Zepbound — can cause two effects that must now be added to the drug's EU product information: dysaesthesia (abnormal skin sensations) and delayed gastric emptying ^[1].

The decision came from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in a document dated 12 December 2024, reference EMA/101887/2025 ^[1]. It followed a review by the EMA's safety committee, the Pharmacovigilance Risk Assessment Committee (PRAC), of the manufacturer's periodic safety update report (PSUR) for tirzepatide covering 14 September 2023 through 13 May 2024 ^[1].

What the regulators found

For both findings, PRAC used the same reasoning. It pointed to data from clinical trials and to spontaneous reports — cases reported by patients and clinicians after the drug reached the market — "including in some cases a close temporal relationship, a positive de-challenge and/or re-challenge," plus a plausible biological mechanism ^[1].

Those terms matter. A "close temporal relationship" means the problem started soon after the drug was taken. A "de-challenge" means the problem eased when the drug was stopped; a "re-challenge" means it came back when the drug was restarted. Regulators treat that pattern as stronger evidence that a drug, rather than something else, is responsible.

On that basis, PRAC concluded that a causal relationship between tirzepatide and dysaesthesia "is at least a reasonable possibility," and reached the identical conclusion for delayed gastric emptying ^[1]. PRAC said the product information for tirzepatide-containing products should be amended accordingly, and CHMP agreed with PRAC's conclusions and grounds ^[1].

Importantly, the CHMP did not change its overall view of the medicine. It stated that the benefit-risk balance of tirzepatide products is "unchanged subject to the proposed changes to the product information," and recommended that the terms of the marketing authorisation be varied ^[1]. In plain terms: the drug stays on the EU market, with updated labeling.

The EMA document is short and does not include case counts, incidence rates, patient characteristics, or the specific wording that will appear in the updated EU label ^[1]. Dysaesthesia (spelled dysesthesia in the US) generally refers to an abnormal and often unpleasant sensation such as burning or tingling, but the document does not describe individual cases or how severe they were ^[1]. Delayed gastric emptying means food leaves the stomach more slowly than normal — a known pharmacologic effect of this drug class that can worsen nausea, vomiting and fullness.

Why it matters for patients

The practical significance is the gap between labels on either side of the Atlantic. According to the summary of this development, the US prescribing information for tirzepatide lists dysesthesia as an adverse reaction with incidence figures, but does not list delayed gastric emptying as an adverse reaction — it appears only in the Clinical Pharmacology section, which describes how the drug works rather than warning about harms. The provided EMA document covers only the European decision and does not address US labeling ^[1], so the exact US wording and numbers are not documented in the source material here.

That divergence can affect what a US patient reads in the leaflet, what a prescriber sees in the label, and how a symptom is framed — as an expected pharmacologic effect or as a recognized adverse reaction. It does not change what the drug does in the body. For anyone weighing tirzepatide, it is one more reason that new or persistent symptoms are worth raising with a clinician rather than interpreting from a package insert alone.

What happens next

The CHMP recommendation dated 12 December 2024 directs the marketing authorisation to be varied and the EU product information updated ^[1]. The document does not give a deadline for when revised EU leaflets reach pharmacies ^[1]. Whether the US Food and Drug Administration makes a matching change to the US label is not addressed in the source and is not yet known.